Skip to main content

We are taking the next step!

The last four years, we have undergone an incredible transformation and wanted to thank each and every employee for their hard work, inspiration and dedication to create a modern company – ready to perform. Performance for people is our main goal, supporting clients by overcoming challenges of their daily life and helping patients all over the world.

Over the years, our colleagues showcased great teamwork and resilience. 2021 and 2022 were special for us, once we launched our new brand representing our core values and strengthen our market approach by enabling us to demonstrate who we are and how we work. Second, 2022 marked our 25th anniversary of being in business underlining the success story of Proinnovera.

Now it is the right time to take the next step by merging with Symbio & Dow Group to form Symbio Proinnovera, a world´s leading specialized dermatology-focused CRO.

With this merger we want to thank our visionary founder Dr. Burkhard Breuer whose foresight and leadership have been instrumental in guiding us throughout the last 25 years. Another big thank you to our management team, led by Dr. Dominique Manu and Erik Kolb, whose relentless dedication and strategic acumen have been pivotal in transforming the organization and steering this merger towards success.

This change does also mean a change in our management structure. Dr. Dominique Manu and Erik Kolb will leave the company and start in new positions as effective of today. Again, a big thank you to both for leading us towards these exciting times. Dr. Burkhard Breuer will continue to support us as a management consultant during the integration phase of the two companies.

We are looking forward to our new venture and believe that Symbio Proinnovera will set benchmarks in the industry.